These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33009738)

  • 1. Linezolid: a Promising Agent for the Treatment of Multiple and Extensively Drug-Resistant Tuberculosis.
    Fermeli DD; Marantos TD; Liarakos AD; Panayiotakopoulos GD; Dedes VK; Panoutsopoulos GI
    Folia Med (Plovdiv); 2020 Sep; 62(3):444-452. PubMed ID: 33009738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of
    Zong Z; Jing W; Shi J; Wen S; Zhang T; Huo F; Shang Y; Liang Q; Huang H; Pang Y
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does linezolid have a role in shortening treatment of tuberculosis?
    Yew WW; Chan DP; Chang KC
    Clin Microbiol Infect; 2019 Sep; 25(9):1060-1062. PubMed ID: 31238119
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis.
    Agyeman AA; Ofori-Asenso R
    Ann Clin Microbiol Antimicrob; 2016 Jun; 15(1):41. PubMed ID: 27334498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects of contezolid (MRX-I) against multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis.
    Yang M; Zhan S; Fu L; Wang Y; Zhang P; Deng G
    Drug Discov Ther; 2022 May; 16(2):99-101. PubMed ID: 35418550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS; Kim KJ; Choi H; Lee SH
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman.
    Jaspard M; Elefant-Amoura E; Melonio I; De Montgolfier I; Veziris N; Caumes E
    Emerg Infect Dis; 2017 Oct; 23(10):1731-2. PubMed ID: 28792382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis.
    Imperial MZ; Nedelman JR; Conradie F; Savic RM
    Clin Infect Dis; 2022 May; 74(10):1736-1747. PubMed ID: 34604901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral neuropathy in a diabetic child treated with linezolid for multidrug-resistant tuberculosis: a case report and review of the literature.
    Swaminathan A; du Cros P; Seddon JA; Mirgayosieva S; Asladdin R; Dusmatova Z
    BMC Infect Dis; 2017 Jun; 17(1):417. PubMed ID: 28606115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis receiving a bedaquiline-based treatment regimen.
    Olayanju O; Esmail A; Limberis J; Gina P; Dheda K
    Int J Infect Dis; 2019 Aug; 85():74-79. PubMed ID: 31100421
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of linezolid against clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains from Beijing, China.
    Yang C; Lei H; Wang D; Meng X; He J; Tong A; Zhu L; Jiang Y; Dong M
    Jpn J Infect Dis; 2012; 65(3):240-2. PubMed ID: 22627306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Old antibiotics for emerging multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB).
    Brouqui P; Quenard F; Drancourt M
    Int J Antimicrob Agents; 2017 May; 49(5):554-557. PubMed ID: 28336312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.
    Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS
    Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.
    Park IN; Hong SB; Oh YM; Kim MN; Lim CM; Lee SD; Koh Y; Kim WS; Kim DS; Kim WD; Shim TS
    J Antimicrob Chemother; 2006 Sep; 58(3):701-4. PubMed ID: 16857689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Easier cure for resistant TB.
    Cohen J
    Science; 2017 Feb; 355(6326):677. PubMed ID: 28209851
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical outcomes of linezolid treatment for extensively drug-resistant tuberculosis in Beijing, China: a hospital-based retrospective study.
    Liu Y; Bao P; Wang D; Li Y; Tang L; Zhou Y; Zhao W
    Jpn J Infect Dis; 2015; 68(3):244-7. PubMed ID: 25672406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis.
    Pang Y; Jing W; Lu J; Zong Z; Huo F; Dong L; Dai G; Li Y; Huang H; Chu N
    Diagn Microbiol Infect Dis; 2019 Aug; 94(4):361-364. PubMed ID: 30876684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line drug susceptibilities of multidrug-resistant tuberculosis strains isolated in Thailand: an update.
    Chaiprasert A; Srimuang S; Tingtoy N; Makhao N; Sirirudeeporn P; Tomnongdee N; Theankeaw O; Charoensook S; Leechawengwongs M; Prammananan T
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):961-3. PubMed ID: 25199012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Replacing Linezolid with OTB-658 in Anti-Tuberculosis Regimens in Murine Models.
    Liu H; Zhu H; Fu L; Zhang W; Chen X; Wang B; Guo S; Ding Y; Wang N; Li D; Lu Y
    Antimicrob Agents Chemother; 2023 Feb; 67(2):e0139922. PubMed ID: 36622240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.